

Table S1 A summary of several studies on the predictive effect of FISH on recurrence of bladder cancer at different time nodes before and after BCG perfusion

Study	Pre-BCG			Post-BCG, 6 weeks			Post-BCG, 3 months			Post-BCG, 6 months		
	(t ₀)		HR (95% CI)	(t ₁)		HR (95% CI)	(t ₂)		HR (95% CI)	(t ₃)		HR (95% CI)
	FISH-	FISH+		FISH-	FISH+		FISH-	FISH+		FISH-	FISH+	
	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts	Rec/Pts		
Mengual <i>et al.</i> (1)	5/10	19/55	0.67 (0.25–1.79)				9/36	15/29	3.23 (1.29–8.04)			
Savic <i>et al.</i> (2)	4/20	14/30	1.88 (0.60–5.87)				10/48	12/20	2.54 (1.05–6.17)			
Kamat <i>et al.</i> (3)	9/39	39/95	1.93 (0.93–3.99)	16/72	33/64	2.88 (1.58–5.24)	9/54	31/49	4.56 (2.14–9.71)	4/49	15/22	23.44 (5.26–104.49)
Liem <i>et al.</i> (4)	25/73	18/52	0.95 (0.52–1.75)	28/96	7/17	1.36 (0.59–3.12)	7/48	10/19	5.76 (1.61–20.64)			
Total (5)	43/142	90/232	1.20 (0.81–1.79)	44/168	40/81	2.23 (1.37–3.62)	35/186	68/117	3.70 (2.34–5.83)	4/49	15/22	23.44 (5.26–104.49)

Note: Rec, recurrence; Pts, patients; FISH, Fluorescence in situ hybridization; BCG, Bacillus Calmette-Guérin; HR, Hazard ratio; 95% CI, 95% confidence interval.

References

- Mengual L, Marin-Aguilera M, Ribal MJ, et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. *Eur Urol.* 2007;52(3):752-759.
- Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. *Int J Cancer.* 2009;124(12):2899-2904
- Kamat AM, Dickstein RJ, Messetti F, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. *J Urol.* 2012;187(3):862-867.
- Liem E, Baard J, Cauberg EC, et al. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. *Med Oncol.* 2017;34(10):172.
- Liem E, Oddens JR, Vernooij RWM, et al. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guerin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. *J Urol.* 2020;203(2):283-291.